Compugen to Participate in Stifel 2024 Healthcare Conference
Compugen (Nasdaq: CGEN) announced its participation in the Stifel 2024 Healthcare Conference in New York City. The company's management will engage in a fireside chat scheduled for Monday, November 18, 2024, at 8:35 am ET. The event will be accessible through a live webcast on the Investor Relations section of Compugen's website, with a replay available after the event. Compugen, operating as a clinical-stage cancer immunotherapy company, is known for its pioneering work in computational target discovery.
Compugen (Nasdaq: CGEN) ha annunciato la sua partecipazione alla Conferenza Sanitaria Stifel 2024 a New York City. Il management dell'azienda parteciperà a una chiacchierata informale programmata per lunedì 18 novembre 2024, alle 8:35 ET. L'evento sarà accessibile tramite una diretta web nella sezione Relazioni con gli Investitori del sito di Compugen, con una registrazione disponibile dopo l'evento. Compugen, operante come azienda di immunoterapia oncologica in fase clinica, è conosciuta per il suo lavoro pionieristico nella scoperta di obiettivi computazionali.
Compugen (Nasdaq: CGEN) anunció su participación en la Conferencia de Atención Médica Stifel 2024 en la ciudad de Nueva York. La gestión de la empresa participará en una charla informal programada para el lunes 18 de noviembre de 2024, a las 8:35 a.m. ET. El evento será accesible a través de una transmisión en vivo en la sección de Relaciones con Inversores del sitio web de Compugen, con una repetición disponible después del evento. Compugen, que opera como una empresa de inmunoterapia contra el cáncer en etapa clínica, es conocida por su trabajo pionero en el descubrimiento de objetivos computacionales.
Compugen (Nasdaq: CGEN)은 뉴욕시에서 열리는 Stifel 2024 헬스케어 컨퍼런스에 참여할 것이라고 발표했습니다. 회사의 경영진은 2024년 11월 18일 월요일 오전 8시 35분 ET에 예정된 파이어사이드 채팅에 참여할 예정입니다. 이 행사는 Compugen 웹사이트의 투자자 관계 섹션에서 라이브 웹캐스트를 통해 접근 가능하며, 이벤트 후 다시 보기 옵션도 제공됩니다. 임상 단계의 암 면역 치료 회사인 Compugen은 컴퓨터 기반 목표 발견 분야에서의 선구적인 작업으로 알려져 있습니다.
Compugen (Nasdaq: CGEN) a annoncé sa participation à la Conférence Santé Stifel 2024 qui se tiendra à New York. La direction de l'entreprise participera à une discussion informelle prévue pour le lundi 18 novembre 2024, à 8h35 (ET). L'événement sera accessible via un webinaire en direct dans la section Relations Investisseurs du site de Compugen, avec un replay disponible après l'événement. Compugen, qui opère en tant qu'entreprise d'immunothérapie contre le cancer en phase clinique, est connue pour son travail pionnier dans la découverte de cibles computationnelles.
Compugen (Nasdaq: CGEN) gab seine Teilnahme an der Stifel Healthcare Conference 2024 in New York City bekannt. Das Management des Unternehmens wird an einem informellen Gespräch teilnehmen, das für Montag, den 18. November 2024, um 8:35 Uhr ET geplant ist. Die Veranstaltung wird über ein Live-Streaming im Bereich Investor Relations der Website von Compugen zugänglich sein, mit einer Wiederholung, die nach der Veranstaltung zur Verfügung steht. Compugen, das als Unternehmen für klinische Krebsimmuntherapien tätig ist, ist bekannt für seine wegweisenden Arbeiten im Bereich der computergestützten Zielentdeckung.
- None.
- None.
HOLON,
A live webcast will be accessible on the Investor Relations section of the Compugen website at www.cgen.com. A replay will also be available following the live event.
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery platform (UnigenTM) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, of which the most advanced program, COM503, a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which has been granted IND clearance from the FDA, is licensed to Gilead. Compugen is headquartered in
Company contact:
Yvonne Naughton, Ph.D.
VP, Head of Investor Relations, and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071
View original content:https://www.prnewswire.com/news-releases/compugen-to-participate-in-stifel-2024-healthcare-conference-302301103.html
SOURCE Compugen Ltd.
FAQ
When is Compugen (CGEN) presenting at the Stifel 2024 Healthcare Conference?
How can investors watch Compugen's (CGEN) presentation at the Stifel Healthcare Conference?
What type of presentation will Compugen (CGEN) give at the Stifel 2024 Conference?
Where is the Stifel 2024 Healthcare Conference featuring Compugen (CGEN) being held?
